| Ticker Symbol: |
ABT - USA Markets |
| Stock Last Traded Price: |
$50.50 |
| Stock Last Traded At: |
4/22/2008 9:58am |
| Change: |
-0.03 |
| Opened At: |
$50.55 |
| Day Range: |
$50.73 - $50.45 |
| Volume: |
582134
|
| Page Last Updated: |
4/22/2008 - 9:58am |
- Wyeth profit hurt by generics (Reuters)
- Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System (PR Newswire)
- Boston Scientific reports higher earnings on accounting gain (at MarketWatch)
- Biotech Isn't in the DNA (at BusinessWeek)
- UPDATE - Wyeth profit slips, hurt by generic Protonix (at Reuters)
- [$$] Boston Scientific's Profit More Than Doubles (at The Wall Street Journal Online)
- Boston Scientific reports higher earnings (at MarketWatch)
- Superior Growth at Abbott Labs (Zacks.com)
- Big Deal for Small RNAs (at Motley Fool)
- Bill Gates Foundation's Value Focus Keeps Pace With a Volatile Market (Indie Research)
- Why Now's Not the Time to Buy Abbott Laboratories (at Seeking Alpha)
- Abbott's Not Ailing (at Motley Fool)
- Sector Snap: Weak dollar boosts medical device makers (AP)
- Abbott Labs Finally Turns Potential Into Profit (at Investopedia)
- Premarket Roundup: JPMorgan Chase, Procter & Gamble (AP)
- New Star Analyst Rankings for ABBOTT LABORATORIES (StarMine)
- Ahead of the Bell: Analysts expect good year for Abbott (AP)
- [$$] Abbott Posts Growth in All Sectors (at The Wall Street Journal Online)
- Abbott Up On Strength Overseas (at Forbes.com)
- [$$] Roche Partner's Drug Wins Approval in Japan (at The Wall Street Journal Online)
Wyeth profit hurt by generics (Reuters)
Wyeth posted slightly lower first-quarter earnings on Tuesday, hurt by the recent launch of generic forms of its Protonix ulcer drug, but surprisingly strong sales of other medicines enabled the company to beat Wall Street profit forecasts....
Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System (PR Newswire)
Smiths Medical MD will promote and distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System...
Boston Scientific reports higher earnings on accounting gain (at MarketWatch)...
Biotech Isn't in the DNA (at BusinessWeek)...
UPDATE - Wyeth profit slips, hurt by generic Protonix (at Reuters)...
[$$] Boston Scientific's Profit More Than Doubles (at The Wall Street Journal Online)...
Boston Scientific reports higher earnings (at MarketWatch)...
Superior Growth at Abbott Labs (Zacks.com)...
Big Deal for Small RNAs (at Motley Fool)...
Bill Gates Foundation's Value Focus Keeps Pace With a Volatile Market (Indie Research)
Bill Gates may no longer play a central role at Microsoft, but investors still take notice when he's in the news....
Why Now's Not the Time to Buy Abbott Laboratories (at Seeking Alpha)...
Abbott's Not Ailing (at Motley Fool)...
Sector Snap: Weak dollar boosts medical device makers (AP)
A weaker U.S. dollar helped several medical device makers post first-quarter profit increases this week, with St. Jude Medical Inc. also gaining on higher sales of its heart devices....
Abbott Labs Finally Turns Potential Into Profit (at Investopedia)...
Premarket Roundup: JPMorgan Chase, Procter & Gamble (AP)
An analyst warned investors Thursday to "be cautious" of JPMorgan Chase & Co. in the current economic slump, though he noted the national bank has done the country a "major service" by buying Bear Stearns Cos....
New Star Analyst Rankings for ABBOTT LABORATORIES (StarMine)...
Ahead of the Bell: Analysts expect good year for Abbott (AP)
Analysts expect strong sales of arthritis drug Humira and the Xience V stent to produce a solid year for drug and medical device maker Abbott Laboratories....
[$$] Abbott Posts Growth in All Sectors (at The Wall Street Journal Online)...
Abbott Up On Strength Overseas (at Forbes.com)...
[$$] Roche Partner's Drug Wins Approval in Japan (at The Wall Street Journal Online)... |
